Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial

Ivabradine for the Prevention of Anthracycline-Induced Cardiotoxicity in Female Patients with Primarily Breast Cancer: A Prospective, Randomized, Open-Label Clinical Trial

<i>Background and Objectives:</i> Cancer therapy containing anthracyclines is associated with cancer-treatment-related cardiac dysfunction and heart failure (HF). Conventional cardioprotective medications can be frequently complicated by their blood-pressure-lowering effect. Recently, el...

Full description

Bibliographic Details
Main Authors: Eglė Čiburienė, Sigita Aidietienė, Greta Ščerbickaitė, Eglė Sadauskienė, Diana Sudavičienė, Edita Baltruškevičienė, Birutė Brasiūnienė, Monika Drobnienė, Jelena Čelutkienė
Format: Article
Language:English
Published: MDPI AG 2023-12-01
Series:Medicina
Subjects:
cardio-oncology
cancer-therapy-induced cardiotoxicity
cardiotoxicity prevention
Online Access:https://www.mdpi.com/1648-9144/59/12/2140

Internet

https://www.mdpi.com/1648-9144/59/12/2140

Similar Items